nach oben

Neurological Sciences

Erschienen in:

16.03.2020 | Original Article

Comparison of the efficacy of intramuscular botulinum toxin type-A injection into the pectoralis major and the teres major muscles and suprascapular nerve block for hemiplegic shoulder pain: a prospective, double-blind, randomized, controlled trial

verfasst von: Meliha Kasapoğlu-Aksoy, İlknur Aykurt-Karlıbel, Lale Altan

Erschienen in: Neurological Sciences | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

This study aims to investigate the effect of botulinum toxin-A (BoNT-A) injection into pectoralis major and teres major muscles and suprascapular nerve block (SSNB) on pain, range of motion (ROM), and upper extremity function for (hemiplegic shoulder pain) HSP, and to compare the effectiveness of these two methods.

Materials and methods

Sixty patients with HSP were randomly assigned into 2 groups. The Group 1 (n = 30) received BoNT-A injection into the pectoralis major and teres major, and the Group 2 (n = 30) received SSSB. Patients were evaluated just before the start of the study, and 2 and 6 weeks after the start of the study with visual analog scale (VAS), Modified Ashworth Scale (MASH), the passive ROM, and the Fugl-Meyer Scale (FMS) arm section.

Results

In Group 1, statistically significant improvement was found in all evaluation parameters on 2th and 6th week. Group 2 showed significant improvement in all parameters on week 2 (p < 0.05), and significant improvement was observed in MASH and pain in abduction in the 6th week (p < 0.05). When the groups were compared with each other, a statistically significant difference was observed in MASH, ROM, and FMS parameters on week 2 in favor of Group 1; in all evaluation parameters, there was a statistically significant difference in favor of Group 1 on week 6 (p < 0.05).

Conclusion

We concluded that BoNT-A injection into the pectoralis major and teres major muscles for HSP was equal in the short term and more effective in the middle term compared with SSNB treatment in improving pain, ROM, and function.

Viana R, Pereira S, Mehta S, Miller T, Teasell R (2012) Evidence for therapeutic interventions for hemiplegic shoulder pain during the chronic stage of stroke: a review. Top Stroke Rehabil 19(6):514–522. https://doi.org/10.1310/tsr1906-514 CrossRefPubMed

Kalichman L, Ratmansky M (2011) Underlying pathology and associated factors of hemiplegic shoulder pain. Am J Phys Med Rehabil 90(9):768–780CrossRef

Huang YC, Chang KH, Liou TH, Cheng CW, Lin LF, Huang SW (2017) Effects of Kinesio taping for stroke patients with hemiplegic shoulder pain: a double-blind, randomized, placebo-controlled study. J Rehabil Med 49(3):208–215CrossRef

Aydın T, Şen Eİ, Yardımcı MY, Kesiktaş FN, Öneş K, Paker N (2019) Efficacy of ultrasound-guided suprascapular nerve block treatment in patients with painful hemiplegic shoulder. Neurol Sci 40(5):985–991. https://doi.org/10.1007/s10072-019-03749-y CrossRefPubMed

Choi JG, Shin JH, Kim BR (2016) Botulinum toxin a injection into the Subscapularis muscle to treat intractable hemiplegic shoulder pain. Ann Rehabil Med 40(4):592–599. https://doi.org/10.5535/arm.2016.40.4.592 CrossRefPubMedPubMedCentral

Marciniak CM, Harvey RL, Gagnon CM, Duraski SA, Denby FA, McCarty S, Bravi LA, Polo KM, Fierstein KM (2012) Does Botulinum toxin type a decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity? A randomized, double-blind, placebo-controlled trial. Am J Phys Med Rehabil 91(12):1007–1019. https://doi.org/10.1097/PHM.0b013e31826ecb02 CrossRefPubMed

Yelnik AP, Colle FM, Bonan IV, Vicaut E (2007) Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin a. J Neurol Neurosurg Psychiatry 78(8):845–848CrossRef

Jabbari B (2008) Botulinum neurotoxins in the treatment of refractory pain. Nat Clin Pract Neurol 4(12):676–685CrossRef

Wissel J, Müller J, Dressnandt J et al (2000) Management of spasticity associated pain with botulinum toxin a. J Pain Symptom Manag 20(1):44–49CrossRef

10.

Sencan S, Celenlioglu AE, Karadag-Saygı E, Midi İ, Gunduz OH (2019) Effects of fluoroscopy-guıded intraarticular injectıon, suprascapular nerve block, and combınatıon therapy ın hemıplegıc shoulder pain: a prospective double-blınd, randomızed clınıcal study. Neurol Sci 40(5):939–946. https://doi.org/10.1007/s10072-019-03733-6 CrossRefPubMed

11.

Jeon WH, Park GW, Jeong HJ, Sim YJ (2014) The comparison of effects of suprascapular nerve block, intra-articular steroid injection, and a combination therapy on hemiplegic shoulder pain: pilot study. Ann Rehabil Med 38(2):167–173CrossRef

12.

Boonsong P, Jaroenarpornwatana A, Boonhong J (2009) Preliminary study of suprascapular nerve block (SSNB) in hemiplegic shoulder pain. J Med Assoc Thail 92(12):1669–1674

13.

Hass BM, Bergstrom E, Jamous A, Bennie A (1996) The inter rater reliability of the original and the modified Ashworth scale fort he assessment of spasticity in patients with spinal cord injury. Spinal Cord 34:560–564CrossRef

14.

Craven BC, Morris AR (2010) Modified Ashworth scale reliability for measurement of lower extremity spasticity among patients with SCI. Spinal Cord 48:207–213CrossRef

15.

Price DD, McGrath PA, Rafii A, Buckingham B (1983) The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 17:45–56CrossRef

16.

Fugl Meyer AR, Jaasko L, Leyman I (1975) The post stroke hemiplegic patient. Scand J Rehabil Med 7(1):13–31PubMed

17.

Niessen M, Janssen T, Meskers C, Koppe P, Konijnenbelt M, Veeger D (2008) Kinematics of the contralateral and ipsilateral shoulder: a possible relationship with post-stroke shoulder pain. J Rehabil Med 40:482–486. https://doi.org/10.2340/16501977-0201 CrossRefPubMed

18.

Cui M, Khanijou S, Rubino J, Aoki KR (2004) Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107:125–133CrossRef

19.

Shin MC, Wakita M, Xie DJ (2012) Inhibition of membrane Na+ channels by A type botulinum toxin at femtomolar concentrations in central and peripheral neurons. J Pharmacol Sci 118:33–42CrossRef

20.

de Boer KS, Arwert HJ, de Groot JH, Meskers CG, Mishre AD, Arendzen JH (2008) Shoulder pain and external rotation in spastic hemiplegia do not improve by injection of botulinumtoxin A into the subscapular muscle. J Neurol Neurosurg Psychiatry 79(5):581–583. https://doi.org/10.1136/jnnp.2007.128371 CrossRefPubMed

21.

Kong KH, Neo JJ, Karen SG (2007) A randomized controlled study of botulinum toxin A in the treatment of hemiplegic shoulder pain associated with spasticity. Clin Rehabil 21:28–35CrossRef

22.

Marco E, Duarte E, Vila J, Tejero M, Guillen A, Boza R, Escalada F, Espadaler JM (2007) Is botulınum toxin type a effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. J Rehabil Med 39:440–447CrossRef

23.

Lim JY, Koh JH, Paik NJ (2008) Intramuscular Botulinum toxin-a reduces hemiplegic shoulder pain a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke 39:126–131CrossRef

24.

Adey-Wakeling Z, Crotty M, Shanahan EM (2013) Suprascapular nerve block for shoulder pain in the first year after stroke: a randomized controlled trial. Stroke 44(11):3136–3141CrossRef

25.

Picelli A, Bonazza S, Lobba D, Parolini M, Martini A, Chemello E, Gandolfi M, Polati E, Smania N, Schweiger V (2017) Suprascapular nerve block for the treatment of hemiplegic shoulder pain in patients with long-term chronic stroke: a pilot study. Neurol Sci 38(9):1697–1701. https://doi.org/10.1007/s10072-017-3057-8 CrossRefPubMed

26.

Allen ZA, Shanahan EM, Crotty M (2010) Does suprascapular nerve block reduce shoulder pain following stroke: a double-blind randomised controlled trial with masked outcome assessment. BMC Neurol 10:83. https://doi.org/10.1186/1471-2377-10-83 CrossRefPubMedPubMedCentral

27.

Vorster W, Lange CP, Briët RJ, Labuschagne BC, du Toit DF, Muller CJ, de Beer JF (2008) The sensory branch distribution of the suprascapular nerve: an anatomic study. J Shoulder Elb Surg 17(3):500–502. https://doi.org/10.1016/j.jse.2007.10.008 CrossRef

28.

Lucioni A, Bales GT, Lotan TL, McGehee D, Cook SP, Rapp DE (2008) Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 101:366–370CrossRef

29.

Heikkila HM, Hielm-Bjorkman AK, Morelius M et al (2014) Intra-articular botulinum toxin A for the treatment of osteoarthritic joint pain in dogs: a randomized, double-blinded, placebo-controlled clinical trial. Vet J 200:162–169CrossRef

30.

Hadley HS, Wheeler JL, Petersen SW (2010) Effects of intra-articular botulinum toxin type A (Botox®) in dogs with chronic osteoarthritis. Vet Comp Orthop Traumatol 23:254–258CrossRef

31.

Chang KV, Hung CY, Wu WT, Han DS, Yang RS, Lin CP (2016) Comparison of the effectiveness of suprascapular nerve block with physical therapy, placebo, and intra-articular injection in management of chronic shoulder pain: a meta-analysis of randomized controlled trials. Arch Phys Med Rehabil 97:1366–1380CrossRef

Titel: Comparison of the efficacy of intramuscular botulinum toxin type-A injection into the pectoralis major and the teres major muscles and suprascapular nerve block for hemiplegic shoulder pain: a prospective, double-blind, randomized, controlled trial
verfasst von: Meliha Kasapoğlu-Aksoy
İlknur Aykurt-Karlıbel
Lale Altan
Publikationsdatum: 16.03.2020
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 8/2020
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04334-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Introduction

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2020

Correction to: New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases

Mild encephalitis/encephalopathy with reversible splenial lesion (MERS) in twin sisters with two CD36 frameshift mutations

Cortical venous thrombosis, multiple cortical infarctions, and vaginal bleeding in a Chinese family with hypofibrinogenemia caused by the FGG mutation c.1019C>T: a case report

Interaktionen zwischen Epilepsie- und COVID-19-Medikamenten

Viral encephalitis followed by anti-NMDAR encephalitis with concomitant MOG antibody-positive central nervous system demyelination in a child